Quantcast

Latest Dimebolin Stories

2012-07-31 10:33:19

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients...

2011-02-07 07:00:00

SAN FRANCISCO, Feb. 7, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, at 10:30 a.m. Eastern Time at the Waldorf-Astoria in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases....

2011-01-03 07:00:00

SAN FRANCISCO, Jan. 3, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, at 10:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and...

2010-12-07 07:00:00

SAN FRANCISCO, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that patient enrollment was completed on November 30, 2010 in the CONCERT study, a 12-month, Phase 3 clinical trial in patients with mild-to-moderate Alzheimer's disease (AD) evaluating the potential efficacy of dimebon (latrepirdine*) when added to ongoing treatment with donepezil. Medivation is conducting this study under its collaboration agreement with Pfizer Inc. "Completing...

2010-11-15 09:15:00

BURLINGTON, Mass., Nov. 15, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surprisingly few surveyed neurologists in the EU5 -- France, Germany, Italy, Spain and the United Kingdom -- are familiar with emerging therapies for Alzheimer's disease. Among surveyed neurologists in the EU5, between 26 and 42 percent indicate they are familiar with Pfizer/Medivation's mitochondrial function...

2010-11-05 15:01:00

SAN FRANCISCO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the third quarter ended September 30, 2010. "In the third quarter, we began the expansion of our MDV3100 development program into earlier stage patients with the initiation of the Phase 3 PREVAIL trial, which is enrolling men with advanced prostate cancer who have not yet received chemotherapy. Additionally, we believe that the...

2010-10-19 07:00:00

SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, at 10:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon...

2010-09-14 07:00:00

SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the UBS Global Life Sciences Conference on Tuesday, September 21, at 8:30 a.m. Eastern Time at the Grand Hyatt in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer. Live...

2010-08-09 15:02:00

SAN FRANCISCO, Aug. 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010. "We have made positive progress in our dimebon program over the past few months," said David Hung, MD, president and chief executive officer of Medivation. "In particular, I am pleased to announce that we have completed enrollment in our Phase 3 HORIZON trial in Huntington disease, exceeding our...

2010-08-02 07:00:00

SAN FRANCISCO, Aug. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2010 financial results and provide a general business update on August 9, 2010, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2010 will be released after markets close on August 9, 2010. Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'